SEC Form 3 · accession 0000899243-19-003497

TCR2 THERAPEUTICS INC. · TCRR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Feb 13, 2019

Accepted (ET)

Feb 13, 2019 · 6:28 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001750019

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—		—	24,137	D
Common Stock	holding	—	—		—	14,713	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$0.74	holding	—	—	—	—	Dec 12, 2026	Common Stock	35,732	—	D
Stock Option (Right to Buy)^F3	$0.74	holding	—	—	—	—	Dec 6, 2027	Common Stock	42,346	—	D
Stock Option (Right to Buy)^F4	$5.88	holding	—	—	—	—	Jul 25, 2028	Common Stock	90,720	—	D

F1The shares are subject to a Stock Restriction Agreement dated October 1, 2015. 25% of the shares vested on the first anniversary of the vesting start date of October 1, 2016, with the remainder vesting in 12 equal quarterly installments thereafter.
F2The Reporting Person was granted an option to purchase 50,445 shares on December 13, 2016. 14,713 of such options were previously exercised. 25% of this option vested and became exercisable on December 13, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F325% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F425% of this option shall vest and become exercisable on July 26, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Exhibit 24.1: Power of Attorney